• 🌎 Worldwide
    • 🇺🇸 U.S.
    • 🇨🇦 Canada
    • 🇬🇧 United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments

InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

PR Newswire by PR Newswire
November 8, 2019
in Investments, Marijuana Stocks, Press Releases
THC BioMed Releases Second Quarter Profitable Results

Photo by Pixabay on Pexels.com

36
SHARES
ShareShare

VANCOUVER, Nov. 8, 2019 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN;OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three months ended September 30, 2019, which is the Company’s first quarter of fiscal year 2020 (“1Q20”).

Conference Call & Webcast:

Friday, November 8, 2019 at 9:00 AM Pacific Time, 12:00 PM Eastern Time

Local – Toronto

+1-647-427-7450

Local – Vancouver

+1-778-371-9827

Toll Free – North America

+1-888-231-8191

Conference ID:

4858497

Webcast:  https://event.on24.com/wcc/r/2130453/2F3067289A74B03F88649F9143706484

Replays, Available through November 15, 2019:

Toronto:  

+1-416-849-0833

North America (Toll Free): 

+1-855-859-2056

Playback Passcode:

 4858497 #

The Company’s full financial statements and related MD&A for the three months ended September 30, 2019 will be available at www.sedar.com on November 8, 2019.

“During the first quarter of fiscal 2020, InMed made a significant step with the submission of its Clinical Trial Application to regulatory authorities to seek permission to begin human clinical trials with INM-755,” stated President and Chief Executive Officer, Eric A. Adams. “We continue to make meaningful progress with our lead programs, including INM-755 for EB, INM-088 in glaucoma, and the biosynthesis manufacturing platform. The Company looks forward to communicating our progress on a regular basis to the broader North American and international investment communities,” concluded Mr. Adams.

Research & Development Update:

  • Biosynthesis manufacturing technology. During 1Q20, we continued to optimize fermentation parameters to maximize production yield and to develop a Down Stream Purification process (“DSP”) with contract development manufacturing organizations (“CDMOs”). We remain on-track to conclude these activities by the end of calendar 2019. In addition, the Company continues to work on an “alternative” biosynthetic manufacturing process with one of our CDMOs. These efforts have resulted in the filing of a provisional patent application for an enzyme which could be applied to both our traditional as well as our “alternative” biosynthesis pathways.

  • INM-755 for the treatment of the epidermolysis bullosa (EB). During 1Q20, InMed completed preparations for its first-in-human clinical trial, scheduled to begin by the end of this calendar year. We completed the supporting preclinical safety pharmacology and toxicology studies, set up the European manufacturer of the drug product, and designed the clinical study protocols. These efforts resulted in the November 4th  submission of InMed’s first ever Clinical Trial Application, or CTA, seeking permission to initiate human clinical studies with INM-755. The submission was made in parallel to the independent Ethics Committee and Dutch Regulatory Authority. We plan to initiate the trial immediately after receiving approval.

  • INM-088 for Glaucoma. The Company continues the development of INM-088 for glaucoma including the strengthening of our intellectual property position with the filing of an additional provisional patent application. During 1Q20, the Company completed in vitro testing of INM-088 and initiated several formulations and pharmacology studies. The Company anticipates completing these activities in early 2020.

Results of Operations (expressed in Canadian Dollars):

  • For the three months ended September 30, 2019, the Company recorded a net loss of $3.89 million, or $0.02 per share, compared with a net loss of $2.84 million, or $0.02 per share, for the three months ended September 30, 2018.

  • Research and development expenses were $2.33 million for 1Q20, compared with $0.63 million for the three months ended September 30, 2018. The increase in research and development expenses in 1Q20 as compared to the same quarter in 2018 was primarily due to increased spending on INM-755 for clinical trial enabling preclinical safety pharmacology and toxicology studies. These studies are required for the regulatory filing to begin human clinical trials which we plan to initiate later this calendar year. In addition, we incurred higher costs for the purchase of the active pharmaceutical ingredients in INM-755 in advance of the planned clinical trials.

  • The Company incurred general and administrative expenses of $0.96 million for 1Q20, compared with $0.81 million for the three months ended September 30, 2018. This increase in general and administrative expenses was primarily due to increased accounting and legal expenses pertaining to certain corporate initiatives.

  • The Company also incurred non-cash, share-based payments, in connection with the grant of stock options, of $0.65 million for 1Q20, compared with $1.42 million for the three months ended September 30, 2018.

  • At September 30, 2019, the Company’s cash, cash equivalents and short-term investments were $14.77 million, which compares to $18.04 million at June 30, 2019. The $3.27 million decrease in cash, cash equivalents and short-term investments during the three months to September 30, 2019, was primarily due to cash outflows from operating activities.

  • At September 30, 2019, the Company’s total issued and outstanding shares were 172,283,633. Including outstanding stock options and warrants, as at September 30, 2019, the Company had 209,673,774 shares on a fully diluted basis. During the three months ending September 30, 2019, the weighted average number of common shares was 172,283,633, which is used for the calculation of loss per share for the quarter.

Table 1:  Condensed consolidated statements of financial position (un-audited):

InMed Pharmaceuticals Inc. 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (un-audited)

As at Septemebr 30, 2019 and June 30, 2019

Expressed in Canadian Dollars

September 30,

June 30,

2019

2019

Audited

ASSETS

Current

Cash and cash equivalents

$

14,708,963

$

12,873,961

Short-term investments

57,925

5,165,093

Accounts receivable

40,088

84,987

Prepaids and advances

248,306

424,275

Total current assets

15,055,282

18,548,316

Non-Current

Property and equipment, net

647,391

55,829

Intangible assets, net

1,159,871

1,184,720

Total Assets

$

16,862,544

$

19,788,865

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current

Accounts payables and accrued liabilities

1,367,868

1,562,865

Current portion of lease obligations

94,205

–

Total current liabilities

1,462,073

1,562,865

Non-current

Lease obligations

409,719

–

1,871,792

1,562,865

SHAREHOLDERS’ EQUITY

Share capital

68,579,890

68,579,890

Contributed surplus

14,867,791

14,216,224

Accumulated deficit

(68,456,929)

(64,570,114)

14,990,752

18,226,000

$

16,862,544

$

19,788,865

Table 2:  Condensed consolidated statements of operations and comprehensive loss (un-audited):

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  (un-audited)

For the three months ended Septmber 30, 2019 and 2018

Expressed in Canadian Dollars

Three Months Ended

September 30, 

2019

2018

Expenses

Research and development

$

2,331,788

$

627,094

General and administrative

958,331

813,036

Amortization and depreciation

43,284

31,041

Share-based payments

651,567

1,423,790

Total operating expenses

3,984,970

2,894,961

Other Income (Loss)

Interest income

77,119

110,573

Foreign exchange gain (loss)

21,036

(56,836)

Total net and comprehensive loss for the period

$

(3,886,815)

$

(2,841,224)

Basic and diluted loss per share for the period

$

(0.02)

$

(0.02)

Basic and diluted weighted average number of common shares outstanding

172,283,633

170,856,278

Table 3:  Condensed consolidated statements of cash flows (un-audited):

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (un-audited)

For the years ended June 30

Expressed in Canadian Dollars

2019

2018

OPERATING ACTIVITIES

Cash flows from operating activities

Net loss for the year

$

(3,886,815)

$

(2,841,224)

Adjustments to reconcile loss to net cash used in operating activities

Amortization and depreciation

43,284

31,041

Share-based payments

651,567

1,423,790

Loss on sales of assets

1,070

–

Accrued interest income on short-term investments

107,168

(13,487)

Changes in non-cash working capital balances:

Prepaids and advances

111,053

(7,517)

Accounts receivable

44,899

33,052

Accounts payable and accrued liabilities

(194,997)

(347,335)

Total cash outflows from operating activities

(3,122,771)

(1,721,680)

Cash Flows From Investing Activities

Purchase of short-term investments

5,000,000

(5,028,752)

Purchase of property and equipment

(42,953)

(2,849)

Proceeds on disposal of property and equipment

726

–

Total cash outflows from investing activities

4,957,773

(5,031,601)

Cash Flows From Financing Activities

Shares issued for cash

–

11,250

Cash provided by financing activities

–

11,250

Increase in cash during the year

1,835,002

(6,742,031)

Cash and cash equivalents beginning of the year

12,873,961

24,134,277

Cash and cash equivalents end of the year

$

14,708,963

$

17,392,246

The Company’s full financial statements and related MD&A for the three months ended September 30, 2019 are available at www.sedar.com.

About InMed:
InMed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids, as well as a pipeline of medications that target diseases with high unmet medical needs.  For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: making further progress on our lead programs; optimizing biosynthesis fermentation parameters to maximize production yield and to develop a Down Stream Purification process with contract development manufacturing organizations and concluding these activities by the end of calendar 2019; developing an “alternative” biosynthetic manufacturing process, including an enzyme which could be applied to both the “traditional” or the “alternative” biosynthesis pathways; obtaining regulatory approval to commence INM-755 clinical trials and initiating the trials immediately following approval; completing planned formulations and pharmacology studies with INM-088 in early 2020; and developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs;.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; the ability to contract with suitable partners; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: preclinical and clinical testing may not produce the desired results on a timely basis, or at all; regulatory applications may not be approved on a timely basis, or at all; cannabis licensing/importing issues may delay our projected development timelines; suitable partners may not be located; economic or market conditions may worsen; our existing cash runway may not allow us to complete our forthcoming significant milestones; the development of a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs may not be as successful as desired, if at all. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: earnings announcementsInMed Pharmaceuticals Inc.OTC:IMLFFTSX:IN

Get Real-Time Updates from MJobserver.com

Unsubscribe
PR Newswire

PR Newswire

PR Newswire empowers communicators to identify and engage with key influencers, craft and distribute meaningful stories, and measure the financial impact of their efforts. Cision is a leading global provider of earned media software and services to public relations and marketing communications professionals.

Related Posts

Cannabis News - Marijuana Becomes Legal in Michigan Starting December 6th
Investments

Acreage Announces Fourth Quarter And Full Year 2020 Earnings Date

February 8, 2021
Cannabis Stock Earnings News
Briefs

Grapefruit USA, Inc. Announces Preliminary Revenue Growth of 714% for Calendar Year 2020 Over Calendar Year 2019

February 8, 2021
Khiron Life Sciences Corp KHRN KHRNF Cannabis Stock News
Press Releases

Khiron Announces Live Webcast and Upcoming Investor Events

February 4, 2021
Cannabis Stocks Earnings Announcement
Investments

Green Thumb Industries to Hold Second Quarter 2020 Earnings Conference Call on August 12, 2020

July 15, 2020
Amended: Naturally Splendid Closes Private Placement and Secures Laboratory Facility
Investments

MediPharm Labs Reports First Quarter 2020 Results, Clears Path for International Growth

June 18, 2020
Cannabis Stock Earnings News
Press Releases

CB2 Insights Announces Delay in Filing Financials and Year End 2019 Financial Results Conference Call

June 10, 2020
Load More
Next Post
RAMM Pharma Corp. Commences Trading on the Canadian Securities Exchange Under Ticker Symbol “RAMM” and Provides Corporate Update

RAMM Pharma Corp. Commences Trading on the Canadian Securities Exchange Under Ticker Symbol “RAMM” and Provides Corporate Update

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

🚨 Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

✉️ Subscribe to Our Newsletter!

* indicates required

🔎 Search Marijuana Stocks

📰 Recent News

  • Verano Holdings Enters into Agreement to Expand Arizona Footprint
  • Green Thumb Industries Announces Initial Public Offering in the U.S. to Raise US$100,000,000
  • Greenlane Announces Dismissal of Remaining Securities Class Action
  • Indiva Reports Record Market Share for January 2021
  • Acreage Announces Fourth Quarter And Full Year 2020 Earnings Date
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • 🇺🇸 United States
  • 🇨🇦 Canada
  • 🇬🇧 United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • 📅 Calendar
  • 📊 Databases
  • 📇 Directories
  • 🔔 RSS Feeds
  • 📺 Videos

Find Cannabis Business Services

  • ⚖️ Attorneys & Law Firms
  • 📊 Accountants & Accounting Firms
  • 💡 Consultants & Consulting Firms
  • 📲 Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • 👀 Advertise
  • 📣 DMO Newswire
  • 📇 List in Our Databases

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.